

**First line of title**  
**second line of title**

---

Master Thesis in Biostatistics (STA495)

by

Name of student  
Matriculation number

supervised by

Name of responsible supervisor (with title)  
Name of supervisor (with title and affiliation if external)

Zurich, month year



# Publication Bias in the Cochrane Database of Systematic Reviews

Giulachin Kreiliger

Version June 28, 2019



# Contents

<b>Preface</b>	<b>iii</b>
<b>1 Introduction</b>	<b>1</b>
<b>2 The Cochrane Dataset</b>	<b>3</b>
2.1 Cochrane Systematic Reviews . . . . .	3
2.2 Data Tidying and Processing . . . . .	9
<b>3 Results</b>	<b>13</b>
3.1 Small Study Effect and Excess of Singificance Tests . . . . .	13
3.2 Small Study Effects Adjustment . . . . .	17
<b>4 Methods</b>	<b>21</b>
4.1 Introduction and Notation . . . . .	21
4.2 Effect Measures and $p$ -values . . . . .	21
4.3 Fixed and Random Effects Meta-Analysis . . . . .	23
4.4 Small Study Effects Tests . . . . .	24
4.5 Small Study Effect and Publication Bias Adjustment . . . . .	29
4.6 Transformation between effect sizes . . . . .	31
<b>A Appendix</b>	<b>33</b>
<b>Bibliography</b>	<b>35</b>



# Preface

Giulachin Kreiliger  
June 2019





# Chapter 1

## Introduction

Typically, we expect empirical scientific results to be distorted by random noise, such that the results are not equal to the real process that they describe. Additionally, one can reasonably assume that the results are also biased to some extent, as the statistical paradigm of precision versus bias would predict: The smaller the noise part of distortion, the more the result should be distorted by bias. However, the trade-off is not inevitable and can be minimized by scientific rigor and foresightfull experimental design. Large efforts have been made both in theory and practice to improve the quality of experiments and their analysis, such as defining experimental settings that prohibit influence of expectations of the researcher (e.g. blinding) or increase sample size in experiments. The introduction of randomized clinical trials is for example seen nowadays as a benchmark in clinical science, heavily improving the reliability of its findings.

It is more and more considered a new scientific field by itself to think of and argue about circumstances that improve the quality of scientific findings. Statistics is in some sense predestined to contribute to it, because probability and chance concepts are key to understanding of any empirical science.

There are also issues, in which statistics is not thought to be able to contribute much to understanding and to be of little help for solving them. For example, the selective attention that the agents in science are paying to new, strong and clear findings in each science is considered merely a psychological and socialissue. It is often explained by the affinity of humans for stories rather than mere facts and for novelties. The issue that scientific findings get more attention and are more likely to be published, read and cited is known for many years, but has gained new traction in meta science when the so-called reproducibility crisis emerged in (2003 to 2005). Studies such as ... showed that even rigid prosecution of study protocols did often not lead to reproduction of previous results when experiments were repeated, which struck empirical science in its core. Most reasonably, some concluded that it was a large misunderstanding of statistical tools such as the p-value in the scientific community that lead to this situation (...). Although that some measures have been taken since then, and some progress is made, the non-reproducibility of scientific findings remain an acute threat to the relevance and reliability of science. Some even argue that certain scientific fields sooner or later will repeat the experience that for example psychology or medicine have made, and are yet to encounter their own reproducibility crisis (...). Clearly, reproduction of experimental results is the gold standard of testing empirical science, because it reassures the universality and reliability by which certain procedures or effects appear if measured in the correct experimental context. However, there are also problems there. One can almost never fully exclude chance events to have played a major role in negating or reaf-firming the experimental findings (which is of course always the case where noise is present in the data). Furthermore, reproduction studies are generally costly and the precise experimental conditions might be hard to reproduce because of lack of information or other reasons.

There is another way to assess the strength of scientific results if the experiment has been conducted more than once (however not with exactly identical protocol as in reproduction studies):

Meta-analyses. In a meta-analyses, results of multiple (fairly identical) experiments (studies) are summarized to a single result. Very often, meta-analyses are not only regarded to be a synthesis of results, but of evidence, thus reflecting the overall and summarized evidence regarding to a scientific question. It is on purpose that selective attention to positive, strong results in the scientific literature have been mentioned beforehand, because it is clear how they will affect this second way of reassurance of scientific findings: The meta-analysis will again lead to irreproducible findings if it is based on a set of results that is itself biased. Thus, meta-analysis will in this case not reach its purpose of assessing reliability of science, but worsen the problem by reinforcing the confidence in the overestimated over-optimistic effects. However, and this is the main topic in this masters thesis, there are some ways to detect irregularities in the body of results that can provide indirect hints that a selective rather than a random sample from a hypothetical population of experiments is present. The abundance of the methods to link some features of the sample of experiments to publication bias, as the tendency of scientific literature to over-proportionally include large effects is generally called, also speaks for the relevance of the topic. A review in 2017 (...) for example identified 147 (!) conceptually differing methods.

This speaks as well for the inevitable difficulties that such methods encounter. First of all, it is most often impossible to estimate the real selection process, that is the rate by which smaller effects go unnoticed because of selective publication and reporting, because the number of missing results in the studies is not known at the first place and impossible to retrieve. Secondly, there is almost no real world data of complete and unbiased meta-analyses, such that evaluations of methods is dependent on simulations. So we have, after applying the methods, only indirect information of publication bias, and the extent to what it might influences scientific findings. Almost all the time, alternative explanations for the results of the methods might relieve the operators and publishers from the reproval of publication bias. However, given the large body of evidence for publication bias collected in other ways, those can probably be expelled most of the time, such that those methods indeed give a quantitative measure of publication bias.

In this masters thesis, the answers for two questions are investigated: What is the extent and effect of publication bias in clinical science? For this purpose, a dataset from the Cochrane Organization is analysed with commonly used techniques to detect and adjust for publication bias (more precisely, small study effects, as it will be seen later). The discussion of the results of the analysis will result in the light of the literature to publication bias.

## Chapter 2

# The Cochrane Dataset

### 2.1 Cochrane Systematic Reviews

The Cochrane Group has specialized on systematic reviews in clinical science. Certain knowledge of standards and principles of the Cochrane Group may help to assess the quality and the properties of the dataset. The following information stems from the Cochrane Handbook for Systematic Reviews ([Higgins JPT, 2011](#)).

The definition of a systematic review is that it “attempts to collate all empirical evidence that fits pre-specified eligibility criteria in order to answer a specific research question.” Thus, the “key properties of a review are”:

- “a clearly stated set of objectives with pre-defined eligibility criteria for studies”
- “an explicit, reproducible methodology”
- “a systematic search that attempts to identify all studies that would meet the eligibility criteria”
- “an assessment of the validity of the findings of the included studies, for example through the assessment of risk of bias”

At the end of a systematic review, “a systematic presentation, and synthesis, of the characteristics and findings of the included studies” is done.

53 Cochrane Review Groups prepare and maintain the reviews within specific areas of health care. A group consists of “researchers, healthcare professionals and people using healthcare services (consumers)”.

The groups are supported by Method Groups, Centers and Fields. The Cochrane Method Groups aim to discuss and consult the groups in methodological questions concerning review preparation. The Centers play a main role in training and support of the Groups. The Fields are responsible for broad medical research areas and follow priorities in those areas by advice and control of the groups.

The first step in a review is writing a protocol, specifying the research question, the methods to be used in literature search and analysis and the eligibility criteria of the study. Changes in protocols are possible but have to be documented and the protocol is published in advance of the publication of the full review. The choices of methodology as well as the changes should not be made “on the basis of how they affect the outcome of the research study”.

In order to avoid potential conflicts of interests, there is a code of conduct that all entities of the Cochrane Organization have to agree on: conflicts of interest must be disclosed and possibly be forwarded to the Cochrane Center, and participation of review authors in the studies used have to be acknowledged. Additionally, a Steering Group publishes a report of potential conflicts of interests based on information about external funding of Cochrane Groups.

In order for keeping the reviews up-to-date, they are revised in a two-year circle with exceptions. In addition to inclusion of new evidence in a field, the revision and maintenance process may as well includes change in analysis methods. This can reflect some advance in clinical science as for example new information about important subgroups, as well as new methods for conducting a Cochrane Review. However, there are no clear guidelines and the Cochrane Groups are free in the rate and extent of up-dating their reviews.

### 2.1.1 Methods for Cochrane Reviews

A research question defines the following points: “the types of population (participants), types of interventions (and comparisons), and the types of outcomes that are of interest”. From the research question, usually the eligibility criteria follow. Usually, outcomes are not part of eligibility criteria, except for special cases such as adverse effect reviews.

The type of study is an important eligibility criterium. The Cochrane Collaboration focuses “primarily on randomized controlled trials”, and also, the methods of study identification in literature search are focused on randomized trials. Furthermore, study characteristics such as blinding of study operators with respect to treatment and cluster-randomizing might be additional eligibility criteria which have to be chosen by the review authors.

After having specified the eligibility criteria, studies have to be collected. The central idea of systematic reviews, and also meta-analyses, is that the collected studies are a random sample of a population of studies, i.e. that they are representative and can be used to assess population properties. Therefore, the search process is crucial, as a selective search result may impose bias on the sample of studies available, making it a non-random sample. For this purpose, the Cochrane Groups are advised to go beyond MEDLINE !!cite!!, because a search restricted to it has been shown to deliver only 30% to 80% of available studies. “Time and budget restraints require the review author to balance the thoroughness of the search with efficiency in use of time and funds and the best way of achieving this balance is to be aware of, and try to minimize, the biases such as publication bias and language bias that can result from restricting searches in different ways.” It is important to note that not only studies, but also study reports are occasionally used in the reviews, as they may provide useful information.

There are different sources that are being used to search for studies.

- The Cochrane Central Register of Controlled Trials is a source of reports of controlled trials. “As of January 2008 (Issue 1, 2008), CENTRAL contains nearly 530,000 citations to reports of trials and other studies potentially eligible for inclusion in Cochrane reviews, of which 310,000 trial reports are from MEDLINE, 50,000 additional trial reports are from EMBASE and the remaining 170,000 are from other sources such as other databases and handsearching.” It includes citations published in many languages, citations only available in conference proceedings, citations from trials registers and trials results registers.
- MEDLINE. MEDLINE includes over 16 million references to journal articles. 5,200 journals publishing in 27 languages are indexed for MEDLINE. PubMed gives access to a free version of MEDLINE with up-to-date citations. NLM gateway such as the Health Services Research Project, Meeting Abstracts and TOXLINE Subset for toxicology citations allows for search in both databases together with additional data from the US National Library of Medicine.
- EMBASE. 4,800 Journals publishing in 30 languages are indexed to EMBASE, which includes more than 11 million records from 1974 onward. EMBASE.com also includes 7 million unique records from MEDLINE (1966 up to date) together with its own records. Additionally, EMBASE Classic allows access to digitized records from 1947 to 1973. EMBASE and MEDLINE each have around 1,800 journals not indexed in the other database.
- Regional or national and subject specific databases can additionally be consulted and

often provide important information. Financial considerations may limit the use of such databases.

- General search engines such as Google Scholar, Intute and Turning Research into Practice (TRIP) database can be used.
- Citation Indexes. The database lists articles published in around 6,000 Journals with articles in which they have been cited and is available online as SciSearch. This form of search is known as cited reference searching.
- Dissertation sources. Dissertations are often listed in MEDLINE or EMBASE but one is advised to also search in specific dissertation sources.
- Grey Literature Databases. Approximately 10% of the results in the Cochrane Database stems from conference abstracts and other grey literature. The Institute for Scientific and Technical Information in France provides access to entries of the previously closed System for Information on Grey Literature database of the European Association for Grey Literature Exploitation). Another source is the Healthcare Management Information Consortium (HMIC) database containing records from the Library and Information Services department of the Department of Health (DH) in England and the King's Fund Information and Library Service. The National Technical Information Service (NTIS) gives access to the results of US and non-US government-sponsored research, as well as technical report for most published results. References from newsletters, magazines and technical and annual reports in behavioral science, psychology and health are provided in the PsycEXTRA database which is linked to PsycINFO database.

### 2.1.2 Structure and Content

The dataset consists of 5016 systematic reviews from the Cochrane Library with 52995 studies and 463820 results. A result compares a clinical or medical intervention or treatments to a control. Each study provides (multiple) results of clinical interventions.

In Table 2.1, two results from a systematic review about effects of barbiturates are shown as they are given in the dataset. As can be seen, further specifications are provided by the variables in the columns.

The comparison variable specifies *what kind* of treatments or interventions are compared, the outcome variable *how* it is compared, and the subgroup variable (not indicated in table) if the result belongs to a certain subgroup. Here, the result is of a binary type, so the counts of events in the barbiturate treatment group and the total number of participants are given in columns "Events" and "Total" and the number of events in the control group "Events\_c" and participants "Total\_c". A event is here death at the end of follow up.

Study	Comparison	Outcome	Events	Total	Events_c	Total_c
Bohn 1989	Barbiturate vs no barbiturate	Death at the end of follow-up	11	41	11	41
Ward 1985	Barbiturate vs no barbiturate	Death at the end of follow-up	14	27	13	26

**Table 2.1:** Example of two results as given in the dataset. Events denotes the count of events in the treatment group while Events c the count of events in the group compared to. Further descriptive variables have been omitted

A complete listing of the variables of a result is given in Table 2.2. They can roughly be separated into variables that *specify the review* in which the result is contained and variables that *specify the result* itself (separated by a horizontal line in Table 2.2):

Results are part of studies that are again part of a (systematic) review. This structure of a review is shown in Figure ??.

Variable	Description
<code>file.nr</code>	The number of the file from which the review data has been gathered. This file corresponds to a file available in the. Cochrane library
<code>doi</code>	Digital object identifier. A unique id of the review such that the full text of the review can be found on the web.
<code>file.index</code>	Internal index of the file in the Cochrane library.
<code>file.version</code>	Denotes the version of the review, since the reviews are occasionally updated.
<code>study.name</code>	Name of the study to which the result belongs
<code>study.year</code>	Year in which the study was published
<code>comparison.name/.nr</code>	Specification of the interventions compared in the study and a unique number for the comparison
<code>outcome.name/.nr</code>	Specification by which outcome the interventions are compared and a unique number for the outcome
<code>subgroup.name/.nr</code>	Potentially indication of affiliation to subgroups and a unique number for the subgroup
<code>outcome.measure</code>	Indication of the quantification method of the effect (of one intervention compared to the other).
<code>effect</code>	Measure of the effect given in the quantity denoted by <code>outcome.measure</code> .
<code>se</code>	Standard error of the measure of the effect,
<code>events1/events2</code>	The counts of patients with an outcome <i>if</i> measurement/outcome is binary or dichotomous 2 (1 for treatment group and 2 for control group).
<code>total1/total2</code>	Number of patients in groups.
<code>mean1/mean2</code>	Mean of patient measurements <i>if</i> outcome is continuous.
<code>sd1/sd2</code>	Standard deviation of mean <i>if</i> outcome is continuous.

Table 2.2: Dataset variable names and descriptions




Figure 2.1: Structure of a hypothetical review with two different comparisons

The structure of a review will now be outlined based on an example of the dataset. Let us consider the previously mentioned barbiturate and head injury review. The aim was to “assess the effects of barbiturates in reducing mortality, disability and raised ICP (intra-cranial pressure) in people with acute traumatic brain injury” as well as to “quantify any side effects resulting from the use of barbiturates”.

The review comprises five studies in total. Three of them compared barbiturate to placebo,

one compared barbiturate to Mannitol and one Pentobarbital to Thiopental. The studies have different outcomes, for example, death or death and severe disability at follow up, but also dropout counts or adverse effects (secondary outcomes). We have continuous (e.g. mean body temperature) and binary outcome data (e.g. death/no death). One study split up outcomes for patients with and without haematoma, which would be subgroups. Thus, it is important not to confuse results with studies. A study can contribute multiple results to a systematic review, for example, primary and secondary outcomes and adverse effects.

Study	Comparison	Outcome
Bohn 1989	Barbiturate vs no barbiturate	Death at the end of follow-up
Bohn 1989	Barbiturate vs no barbiturate	Death or severe disability at the end of follow-up
Eisenberg 1988	Barbiturate vs no barbiturate	Death at the end of follow-up
Eisenberg 1988	Barbiturate vs no barbiturate	Uncontrolled ICP during treatment
Eisenberg 1988	Barbiturate vs no barbiturate	Hypotension during treatment
Perez-Barcena 2008	Pentobarbital vs Thiopental	Death at the end of follow-up (6 months)
Perez-Barcena 2008	Pentobarbital vs Thiopental	Death or severe disability at the end of follow-up (6 months)
Perez-Barcena 2008	Pentobarbital vs Thiopental	Uncontrolled ICP during treatment
Perez-Barcena 2008	Pentobarbital vs Thiopental	Hypotension during treatment
Schwartz 1984	Barbiturate vs Mannitol	Death at the end of follow-up (1 year)
Schwartz 1984	Barbiturate vs Mannitol	Death at the end of follow-up (1 year)
Schwartz 1984	Barbiturate vs Mannitol	Uncontrolled ICP during treatment
Ward 1985	Barbiturate vs no barbiturate	Death at the end of follow-up
Ward 1985	Barbiturate vs no barbiturate	Death or severe disability at the end of follow-up
Ward 1985	Barbiturate vs no barbiturate	Mean ICP during treatment
Ward 1985	Barbiturate vs no barbiturate	Mean arterial pressure during treatment
Ward 1985	Barbiturate vs no barbiturate	Hypotension during treatment
Ward 1985	Barbiturate vs no barbiturate	Mean body temperature during treatment

**Table 2.3:** Barbiturate and head injury review. In the columns, study names, comparison and outcome measure of the results are given

Information about missing values in the dataset is given in Table 2.4. For variables as research subject, outcome and subgroup name and event counts there are no missing values. The relative amount of missing values is very low except for study years. For continuous outcomes, the cases have been counted where no treatment effect and standard error is available: neither mean values and standard deviations, nor mean differences and standard error. Also Study years before 1920 and after 2019 are declared as missing, as well as sample sizes below zero.

Missing mean values and mean differences	984
Missing standard deviations and standard errors	1300
Missing sample sizes	12173
Missing study year	44649

**Table 2.4:** Number of missing variables and measurements in the dataset

The studies that are included in the reviews and have been published are most often from the years after 1980 (5% quantile = 1983). The median of the publication years is 2003, the mean 2001.03 and the quartiles are 1996 and 2008. Only a handful ( $n = 18$ ) have been published in 2018, none in 2019.

The top treatment effect measure (risk ratio, mean difference, hazard ratio etc.) abundances are summarized in Table 2.5. One can conclude of the table that roughly 30 % of outcomes in the dataset are continuous and the rest being some sort of discrete or binary outcomes, most often binary ( $> 65\%$ ).

The sample sizes among results vary to some extent. There are 5% of treatment group sample sizes that are smaller than 8, the 5% quantile. The first quartile is 22, the median 48, the mean 302.03 and the third quartile 119. The large difference between median and mean is caused by very large groups with over 2,000,000 participants. Analogously, the quantiles of the total sample

Outcome measure	n	Percentage
Risk Ratio	232583	50.1%
Mean Difference	102315	22.1%
Odds Ratio	49372	10.6%
Std. Mean Difference	40535	8.7%
Peto Odds Ratio	19122	4.1%
Hazard Ratio	6566	1.4%
Risk Difference	6234	1.3%
Rate Ratio	2283	0.5%
other	4810	1%

**Table 2.5:** Frequencies of outcome measures among results.  $n$  denotes the total number of results with the outcome measure and percentage the percentage of the outcome measure,

size are: 5% quantile = 15, first quartile = 44, median = 94 and third quartile = 229. The mean is 617.81.

The mean and median number of results per review are 12.42 and 7. There are 417 reviews with five or fewer results, and the quartiles are 16 and 102. Similarly, the number of reviews with a maximum of two studies included is 836, the mean study number is 12.42, the median 7 and the interquartile range 4 and 15. The discrepancy between mean and median is due to large reviews with a high number of studies and results, most extreme in ? which is a systematic review about antibiotic prophylaxis for preventing infection after cesarean section, with 95 studies and 1497 results in total.

For results to be suitable for usage in meta-analysis, they have to be identical with respect to comparison and outcome. More specifically, the studies in the dataset that have the same comparison, outcome and subgroup can be pooled in a meta-analysis, since their research subject and experimental setup can be considered sufficiently homogeneous. Importantly, this distinction is also used by the Cochrane Organization itself, i.e. the meta-analyses are identical to the meta-analyses done in the systematic reviews.

The dataset is divided in meta-analyses with identical experimental setup. The size of a meta-analysis denotes how many results are included in a group. Table 2.6 shows the number of meta-analysis with size  $\geq n$  results. Practically, this number of meta analyses can be performed, with each having at least  $n$  results:

n	Number of groups	Cumulative sum of groups
1	102344	186300
2	31686	83956
3	16072	52270
4	9628	36198
5	6444	26570
6	4230	20126
7	2961	15896
8	2114	12935
9	1592	10821
10	1238	9229
11	921	7991
12	702	7070
13	585	6368
14	455	5783
15	5328	5328

**Table 2.6:** Cumulative number of groups with number of reproduction trials  $\geq n$



## 2.2 Data Tidying and Processing

The original dataset was provided by .. (some words how the dataset was obtained and processed by C.R.).

The information in the previous pages are from a tidied and processed version of this dataset.

### 2.2.1 Modification of old variables

In some cases, reasonable assumptions led to small changes in the originally provided variables:

- **study.year**: It was assumed that studies that are declared to have been published before 1920 ( $n = 30664$ ) are mis-specified, as well as after 2019 ( $n = 384$ ), so these have been set to NA.
- **mean1** and **mean2**: When both **mean1** and **mean2** are equal to zero or NA, **outcome.measure.new** is equal to (Std.) Mean Difference, but a mean difference is given in effect, **mean1** is set equal to effect ( $n = 1593$ ).

### 2.2.2 Newly Introduced Variables

Some new variables are added to the obtained dataset:

- **outcome.measure.new**: Outcome measure specifications given in **outcome.measure** were standardized whenever they were supposed to denote the same outcome measure. An example would be the formally different notations for odds ratios: “Odds Ratio”, “odds ratio”, “OR”, which were all denoted as “Odds Ratio”.
- **outcome.type**: A simplification of **outcome.measure.new**. The **outcome.type** “bin” indicates if **outcome.measure.new** is either one of “Risk Ratio”, “Odds Ratio”, “Risk difference” or “Peto Odds Ratio”. “cont” is equivalent to **outcome.measure.new** equal to “Std. Mean Difference” or “Mean Difference”. “surv” equal to “Hazard Ratio” and “rate” equal to “Rate Ratio” or “Rate Difference”.
- **lrr** and **var.lrr**: log risk ratio and variance of the log risk ratio for **outcome.type** “bin”.
- **smd** and **var.smd**: Hedges  $g$  and the variance of Hedges  $g$  for **outcome.type** “cont”. If not computable from **mean1**, **mean2**, **sd1** and **sd2**, and **outcome.measure.new** was equal to “Std. Mean Difference”, it was set equal to effect (and **var.smd** equal to **se** squared,  $n = 6938$ ).
- **smd.ord1** and **var.smd.ord1**: Cohen’s  $d$  and its variance as obtained by transformation of a log odds ratio for **outcome.type** “bin”.
- **cor.Pearson** and **var.cor.Pearson**: Pearson correlation coefficient and variance as obtained from the  $d$  (for **outcome.type** “bin”) or  $g$  (for **outcome.type** “cont”) to  $r$  transformation.
- **z** and **var.z**: Fisher’s  $z$  score and its variance obtained from the Pearson correlation  $r$  to  $z$  transformation.
- **pval.single**:  $p$ -value against the null hypothesis of no treatment effect, derived by a  $t$ -test for **outcome.type** “cont” or Wald test for **outcome.type** “bin”.
- **events1c** and **events2c**: Correction of **events1** and **events2** zero event counts or event counts = patient number. When no events occurred, 0.5 was added, and when all patients experienced the event, 0.5 was subtracted. When one of **events** had zero counts while the other had maximum counts, no adjustment occurred.

- **meta.id:** Meta-analysis ID variable to uniquely identify any potential meta-analysis in the dataset. Consistent to what has been discussed before, all results that share a common comparison, outcome and subgroup (optional, subgroups not given in any case) may be combined in a meta-analysis.

### 2.2.3 Eligibility criteria for Publication Bias Test and Adjustment

Initially, the analysis is restricted to binary, continuous and survival outcomes. More formally:

- **Outcome measures:** The analysis has been restricted on the following outcome measures (from `outcome.measure.new`): “Odds Ratio”, “Risk Ratio”, “Risk difference”, “Peto Odds Ratio”, “Std. Mean Difference”, “Mean Difference”, “Hazard Ratio” ( $n = 456727$  out of a total of 463820 results)

The suggestions of criteria for eligibility for publication bias tests of [Ioannidis and Trikalinos \(2007a\)](#) have largely been followed:

- **Sample size:** A meta-analysis is comprised of at least ten studies ( $n = 5797$  remaining).
- **Heterogeneity:** The  $I^2$  statistic of a given meta-analysis is smaller than 0.5, thus, the proportion of between study variance of the overall variance is smaller than 0.5 ( $n = 4038$  remaining).
- **Study size:** The ratio between largest variance of an estimate and smallest variance of an estimate is larger than four ( $n = 4006$  remaining).
- **Significance:** At least one treatment effect has a  $p$ -value below the significance threshold 0.05 ( $n = 2673$  remaining)

After having excluded meta-analyses with less than ten studies, additional criteria for excluding inconvenient meta-analyses are:

- **Sensitivity Analyses:** When the same results are used multiple times for different meta-analyses, only one is retained. More precisely, if a study has the same `study.name` and same `effect`, it was considered a duplicate, and the smaller meta-analysis of the two was excluded. The intention is to exclude sensitivity analyses which are operated on subsets of the available results.
- **Zero events:** In the case of binary outcomes, meta-analyses with zero events in any study and any group are excluded ( $n = 141$  out of meta-analyses with at least ten studies).
- **Missing means and sd's:** In the case of continuous outcomes, meta-analyses with means and sd's in any group being equal to zero are excluded ( $n = 306$  out of meta-analyses with at least ten studies).
- **Single patient data:** Meta-analyses that are comprised of single patient data are excluded ( $n = 8$  out of meta-analyses with at least ten studies)

–Make Flowchart–

### Exclusions due to Computational Errors

In exceptional cases, the applied meta-analysis methods and publication bias tests and adjustment algorithms failed due to various reasons. Here, those cases are listed and if known, the reasons why computation failed are given.

**Binary Outcomes:** Out of the meta-analyses that are of `outcome.type` bin, and have at least ten studies, two studies had to be excluded:

- meta.id = 62301 (file.nr = 1531, comparison.nr = 8, outcome.nr = 6, subgroup.nr = 1): Largest study (se = 0.1) has risk ratio 1 and smallest study (se = 1) risk ratio 0.07. Copas publication bias adjustment methods has likelihood optimization issues.
- meta.id = 94519 (2519, 14, 1, 2): Largest study (se = 0.05) has risk ratio 0.9 and smallest study (se = 0.4) risk ratio 3. Again Copas publication bias adjustment methods has likelihood optimization issues.

There were no issues with `outcome.type` “cont” and “surv”. For the subsequent information, it is important to know that meta-analyses are only repeated with Hedges  $g$ , Pearson correlation coefficient and Fisher’s Z-scores, if the outcome type is not survival and all of the above criteria are met ( $n = 0$ ).

**Pearson Correlation Coefficient:** Three studies had to be excluded when analyzing the Pearson correlation coefficients:

- meta.id = 157083 (file.nr = 5061, comparison.nr = 1, outcome.nr = 5, subgroup.nr = 2): A meta-analysis with all results from the same study, and equal sample size (5 each group). The Copas selection model algorithm issued an error when optimizing the likelihood.
- meta.id = 159329 (5183, 3, 13): One very small study with group sizes of 2 and 1 patients and small risk ratio of 0.222 (compared to the largest of 1.05, se = 0.04). Also, the Copas selection model algorithm issued an error when optimizing the likelihood.
- meta.id = 182298 (6211, 1, 8, -): One very small study with 8 patients in each group and 0 event counts in both. The Copas selection model algorithm issued an error when optimizing the likelihood.

**Fisher’s Z score:** The same issues as encountered for Pearson correlation coefficients (meta.id = 157083 and 159329). The variance of the z score  $s_z^2$  can be calculated as:  $s_z^2 = \frac{1}{n-3}$ ,  $n$  being the total sample size. Thus, studies that have total sample size  $n \geq 3$  are discarded in the meta-analyses ( $n = 72$  studies). 2 meta-analyses have then less than 10 studies left for pooling:

- meta.id = 10671: (file.nr = 5061, comparison.nr = 1, outcome.nr = 5, subgroup.nr = 2), 7 studies left.
- meta.id = 43324: (1019, 1, 3, 2), 9 studies left.

### The Publication Bias Test and Adjustment Dataset

The dataset that was ultimately tested and adjusted for publication bias comprises 2673 meta-analyses and 42789 results. ..



# Chapter 3

## Results

### 3.1 Small Study Effect and Excess of Singificance Tests

The meta-analyses fulfilling the criteria from chapter 2, section 2.2, are analysed with small study effects tests and excess significance tests. The  $p$ -values for all meta-analyses can be displayed in histograms. Because the tests are methodologically different, the results of each testing method is displayed separately. Furthermore, the outcome types (as defined previously by the variable `outcome.type`) are also kept separated.

The histograms in Figure 3.1 show that the distributions are (with the exception of Schwarzer's test) skewed to the right for all outcome types, indicating evidence for small study effects and excess significance. Moreover, the excess significance tests have a mode around  $p = 0.4$ . The large differences between small study effect tests for binary and continuous outcomes will be subject to discussion.


"Excess significance" denotes the excess of significance  $p$ -values from the test of Ioannidis and Trikalinos (2007b), see ???. For continuous and survival outcomes, the names refer to:

- Egger's test, the weighed linear regression test as described in section 4.4.1
- Thompson and Sharp's test, the weighted linear regression test adjusted for between-study heterogeneity, section 4.4.1
- Begg and Mazumdar's test, the rank test described in section 4.4.1

For binary outcomes, the names refer to:

- Harbord's test, the likelihood score based test (section 4.4.2)
- Peter's test, the weighted linear regression with inverse sample size as explanatory variable (study size proxy) described in section 4.4.2
- Rücker's test, the test based on the arcsine transformation of proportions, in combination with Thompson and Sharp's regression test (section 4.4.2)
- Schwarzer's test, the rank based test using the expected event counts computed with the hypergeometric distribution (section 4.4.2)

It cannot be seen in Figure 3.1 if the tests used are finding small study effects/excess significance for the same meta-analyses. Especially between small study effects and excess significance tests, we expect some disagreement between tests. A simple method to check the coincidence of test results is to compare scatterplots and empirical spearman correlations between test statistics. This is done in Figure 3.2.




**Figure 3.1:** Histogram of the  $p$ -values for small study effect in meta-analyses. The testing method is indicated in the header, binwidth is equal to 0.1. The significant proportion based on the threshold of 0.1 is displayed inside the figures.

Here, there is no separation between survival and continuous outcomes. The upper left rectangle is displaying binary outcomes and the lower right about continuous and survival outcomes.

The observed patterns on the scatterplots differ: Excess significance and small study effect test statistics do usually not align with each other, forming rather randomly scattered bulks of points. Regression based tests as Egger and Thompson which are methodically almost identical are closely aligned, which is also reflected in large correlation coefficients. In general, small study effect tests align, but the extent to which they align differs. Harbord's test statistic has similar correlation coefficients with all other small study effect test statistics for binary outcomes, while the correlation coefficients between them is varying.

Because scatterplots and correlation coefficients can be misleading, also a Tukey mean-difference or Bland-Altman plot is shown for three scenarios in Figure 3.3:

- For Egger's and Thompson's tests, which is supposedly the most similar test and should show the least deviations and systematic errors
- For Harbord's and Rucker's tests



**Figure 3.2:** Pairs-plot for test statistics of small study effect and excess significance. The lower panel gives the spearman correlations for the different test statistics, and the upper panel displays a scatterplot. The colours indicate magnitude and direction of the correlation coefficients. The rectangle with white borders displays the area within which both tests have absolute value  $< 1.96$ .

- For Harbord’s and excess significance tests


This can be justified since all tests are supposed to measure the evidence for publication bias. For the plots, the  $p$ -values of the tests are transformed on the entire continuous scale by a logit transformation. The mean  $p$ -value  $((\text{logit}(p\text{-value } 1) + \text{logit}(p\text{-value } 2))/2)$  is then displayed against the difference between the  $p$ -value. If no systematic errors and biases exist between the measurement methods, then

- the mean of the differences (systematic error) should be around zero
- the points should scatter independent of the mean of the  $p$ -values

The last criterium seems not to be given when comparing Harbords and Excess significance tests. – In the appendix, it can be seen that this is reproducible with the remaining small study effect tests (not there yet) – With decreasing mean, the difference gets more negative, and vice versa, such that one would predict that the excess significance  $p$ -values are more “extreme” in both directions. This finding suggests that correspondence between the tests is poor. The confidence intervals can be used as limits of agreement, which gives, after back-transformation, around 0.9 for Egger and Thompson test, and around 0.99 for Harbord and Rucker.

The previous results suggest that the results will also differ substantially after applying the common dichotomization of  $p$ -values. We expect that some proportion of the meta-analysis will only be significant for a certain test, and this is indeed observed in Table 3.1. It displays the percentage of meta-analyses with a certain number of significant test results.

When only looking at small study effect tests, 29.1% of binary outcome tests and 26.5% of survival and continuous outcome tests had at least one significant result. After applying



**Figure 3.3:** Mean - difference plots for logit transformed  $p$ -values. The mean of logit transformed  $p$ -values is displayed on the  $x$ -axis and the difference on the  $y$ -axis. Blue and red lines display the systematic error and the confidence intervals of the systematic error (limits of agreement).

Count	Binary Outcomes	Continuous and Survival
0	65.9 %	68.4 %
1	16.4 %	9.6 %
2	8.6 %	9.1 %
3	5.6 %	10.6 %
4	2.9 %	2.3 %
5	0.6 %	NA %

**Table 3.1:** Counts Number of significant test results per meta-analysis, separated for outcome types. Last entry for continuous and survival outcomes is empty since one test less was applied

the bonferroni correction for multiple testing, this shrinks to 10.9% for binary and 12.1% for continuous and survival outcomes.

When comparing significant findings for small study effect tests and excess significance tests, we will only do so with Harbord's or Egger's test. 22.4% of binary outcome analyses had at least one of the two test  $p$ -values being significant, and equivalently, 28% for continuous and survival outcomes. Again, the numbers change to 13.3% for binary outcomes and 17.2% for continuous and survival outcomes after applying the bonferroni correction.

3% have significant Harbord's test result and significant excess significance test result (1.1% with bonferroni). Of the continuous outcomes, we have 6.1% with Egger's test and 1.8% with Bonferroni correction.



## 3.2 Small Study Effects Adjustment

### 3.2.1 Change in Effect Size after Adjustment

There are two possibilities when adjusting the pooled treatment effect of meta-analyses for publication bias. The absolute size of the treatment effect can be smaller, or larger after adjustment. Additionally, it is of interest by how much the treatment effect is diminished or increased.

Figure 3.4 displays the difference between the meta-analysis pooled treatment effect  $\theta_M$  and the adjusted treatment effect  $\theta_{Adj.}$  for the copas and regression adjustment methods and fixed and random effects meta-analysis. The treatment effects are mirrored on the positive side, such that a positive difference indicates that the effect size was smaller after adjustment (and analogously, larger if the difference is negative). For better illustration, some very large and very small differences have been omitted in the  $z$ -score and Hedges  $g$  histograms; the missing differences are provided in Table 3.2. Additionally to the histograms, Table 3.3 shows the quantiles and means for the various differences.

Copas estimates are equal to random effect in 1331 for  $z$ -score based analysis, 1144 for Hedges  $g$  based analysis (and 1056 for analysis based on original effect measures).

We see in Figure 3.4 that both reduction and amplification of original effect size occurs frequently. Nevertheless, there are more adjustments towards smaller effects for  $z$ -scores and Hedges  $g$ , regardless of the reference meta-analysis method. Survival outcomes, and  $z$ -scores meta-analyses and copas adjustment differences are exception to this. The larger proportion of reduction is mostly also reflected in the means and medians in Table 3.3. They are mostly around zero or larger, although not to a large extent. There is more extensive downward correction of effect sizes if random effects meta-analysis is used as the reference.


meta.id	file.nr	comparison.nr	subgroup.nr	z fixed	z random	z Copas	z regression	g fixed	g random	g Copas	g regression
2009	2009	1	1	0.31	0.36	0.31	0.43	0.70	0.70	0.70	2.48
2068	2068	2	0	0.29	0.35	0.29	0.43	0.68	0.68	0.68	2.57
18658	18658	2	0	1.16	1.14	1.16	1.17	1.40	2.85	1.40	1.74
46472	46472	1	1	1.79	1.44	1.79	0.66	0.12	6.97	6.97	0.79
52528	52528	1	0	-0.75	-0.69	-0.50	-0.26	-1.19	-1.53	0.18	-0.52
60546	60546	1	1	0.17	0.24	0.17	0.34	0.53	0.53	0.53	1.65
70389	70389	1	1	-0.08	-0.07	15.58	-0.04	-0.13	-0.13	-0.13	-0.05
73769	73769	3	1	-0.14	0.00	214760.42	-0.04	-0.01	-0.12	0.01	0.04
79113	79113	2	0	-0.38	-0.38	-0.38	-0.48	-0.93	-0.93	-2.00	-3.47
90138	90138	3	0	0.31	0.80	0.31	0.55	0.72	0.71	0.71	2.16
97356	97356	2	0	-0.08	-0.33	-0.08	-0.17	-0.42	-0.35	-1.58	-1.82
98030	98030	1	0	-0.09	-0.07	-0.09	-0.04	-0.41	-0.41	-1.50	-2.79
101436	101436	1	5	0.54	0.62	0.80	0.91	1.21	1.21	1.21	2.74
118121	118121	4	1	0.25	0.23	71.80	-0.03	0.44	0.44	0.44	0.14
119537	119537	3	0	0.07	0.15	0.07	0.29	0.50	0.50	1.43	1.81
119818	119818	3	3	-0.25	-0.25	-0.11	-0.04	-0.50	-0.54	28.44	-0.03
146301	146301	1	0	0.14	0.26	498188.34	0.28	0.56	0.37	0.60	0.52

**Table 3.2:** Missing meta-analysis pooled treatment effect and adjusted treatment effects of Figure effig:adjustment.size. Abbreviations are used for  $z$ -score ( $z$ ) and Hedges  $g$  ( $g$ )

### 3.2.2 Change in Evidence for Treatment Effects

Adjustment for small study effects in meta-analysis will not only provide new effect sizes, but also standard errors thereof. Thus, also the evidence for efficacy of a treatment can be obtained, which is usually summarized in a suitable test statistic or  $p$ -value.

The wald test statistics  $p$ -value for fixed and random effects meta-analyses and copas and regression adjusted treatment effects have been calculated. They are shown in Figure 3.5 for meta-analysis based on  $z$ -score, Hedges  $g$  and log hazard ratio. The  $p$ -values get larger changing from fixed effects to random effects, and from Copas to regression adjusted  $p$ -values for  $z$ -scores and Hedges  $g$ . Also, they are larger for Hedges  $g$  based meta-analyses compared to  $z$ -score based meta-analyses. Meanwhile, they stay approximately equal for log odds ratios, with the exception of regression adjusted test statistics. Thus, after adjusting for small study effects, the evidence for treatment efficacy shrinks at least partially, which is also indicated by the smaller number of




**Figure 3.4:** Histogram of the treatment effect differences between meta-analysis and adjusted meta-analysis. Negative differences indicate greater adjusted effect sizes than meta-analysis effect sizes. The bins are centered at zero.

	5%	25%	50%	75%	95%	mean
z-score: Fixed - Copas	-0.05	-0.01	-0.00	0.01	0.05	-402.37
z-score: Random - Copas	-0.01	0.00	0.00	0.00	0.04	-159.98
z-score: Fixed - Regression	-0.13	-0.04	0.01	0.05	0.15	0.01
z-score: Random - Regression	-0.16	-0.03	0.02	0.07	0.18	0.02
Hedges g: Fixed - Copas	-0.05	-0.01	0.00	0.01	0.09	0.02
Hedges g: Random - Copas	-0.00	0.00	0.00	0.00	0.14	0.04
Hedges g: Fixed - Regression	-0.24	-0.04	0.04	0.13	0.39	0.05
Hedges g: Random - Regression	-0.23	-0.03	0.05	0.17	0.43	0.07
Log hazard ratio: Fixed - Copas	-0.03	0.00	0.00	0.00	0.02	-0.01
Log hazard ratio: Random - Copas	-0.03	0.00	0.00	0.00	0.00	-0.01
Log hazard ratio: Fixed - Regression	-0.21	-0.14	-0.07	0.01	0.15	-0.06
Log hazard ratio: Random - Regression	-0.23	-0.15	-0.07	0.03	0.15	-0.06

**Table 3.3:** Quantiles and Means of the differences between meta-analysis pooled treatment effects and small study adjusted treatment effects. The row names indicate which outcome measure, meta-analysis and adjustment method is used

significant  $p$ -values (0.05 threshold). Note that while  $z$ -score and Hedges  $g$  based meta-analyses use the same data, only with different effect measure transformations, this is not true for meta-



**Figure 3.5:** Histogram of the wald test-statistic  $p$ -value of meta-analysis and adjusted pooled treatment effect, based on different treatment effect measures. The method is indicated in the header, binwidth is set to 0.05. The significant proportion based on the threshold of 0.05 is displayed inside the figures.

analyses based on log odds ratios.

@



# Chapter 4

## Methods

### 4.1 Introduction and Notation

The analysis has already been said to be restricted on clinical or health care interventions. The interventions are restricted to comparisons of two treatment arms by some measure of sanity or worsening of health. The difference in this measure between the groups is referred to as the treatment effect. Where it is not particularly mentioned, the term treatment effect refers to any effect measure such as log risk ratio, log hazard ratio, Cohen's  $d$  or Hedges  $g$ , Fisher's  $z$  score or Pearson's correlation coefficient.

Let us consider a meta-analysis with  $n$  study treatment effects ( $n > 1$ , but typically small). A study is indexed by  $i$ , and its treatment effect by  $\theta_i$ . The observed treatment effect is  $\hat{\theta}_i$ . The pooled treatment effect of a meta-analysis will be denoted as  $\theta_M$ , and consequently, the observed pooled treatment effect as  $\hat{\theta}_M$ . Furthermore, each treatment effect is typically measured with some standard error  $s_i$  and an estimate of  $s_i$  is denoted as  $\hat{s}_i$ . The  $\hat{\phantom{x}}$  sign thus indicates if it is an estimate.

For continuous outcomes, let  $m_t$  be the mean of the treatment group,  $m_c$  the mean of the control group, and equivalently  $sd_t$  and  $sd_c$  the corresponding standard deviations.  $n_t$  and  $n_c$  are the total number of participants in the groups. In the case of binary outcomes, let  $e_t$  be the count of events in the treatment arm  $e_c$  the count of events in the control group. The observed counts in a study  $i$  are referred to as  $e_{t,i}$  and analogously  $e_{c,i}$ .

### 4.2 Effect Measures and $p$ -values

#### 4.2.1 Continuous Outcomes

For given  $(m_t, m_c)$ ,  $(sd_t, sd_c)$  and  $(n_t, n_c)$ , one can compute mean difference as well as a standardized mean difference (here: Hedges  $g$ ) and a standard error thereof. Note that the definition of Hedges  $g$  and its standard error  $s$  varies among the literature, the following applies for this report:

$$s = \sqrt{\frac{(n_t - 1)sd_t^2 + (n_c - 1)sd_c^2}{n_t + n_c - 2}} \quad g = \frac{m_t - m_c}{s} \quad (4.1)$$

The mean difference  $\theta$  and its standard error  $s$  can similarly be obtained by

$$\theta = m_t - m_c \quad s = \sqrt{sd_t^2/n_t + sd_c^2/n_c} \quad (4.2)$$

Both estimators take into account that the two groups might have unequal variances. A  $p$ -value to test the null hypothesis that the mean between group is equal is commonly obtained with the students  $t$  test. The  $t$  statistic is obtained, using  $s$  and  $g$  from 4.1, by

$$t = g / (s \sqrt{(1/n_t) + (1/n_c)})$$

and the  $p$ -value can be obtained with the cumulative student's  $t$ -distribution  $F$  with  $n_t + n_c - 2$  degrees of freedom:

$$p = 2(1 - F(|t|))$$

The  $t$ -test is known to be not very reliable if combined sample size is small ( $n < 30$ ), see for example [Kasuya \(2001\)](#).

### 4.2.2 Binary Outcomes

Two commonly used effect measures for binary outcome data are risk ratios and odds ratios between treatment and control group. The methods presented here can also be found, for example, in ([Borenstein et al., 2011](#), 34). Let  $\theta$  be the logarithm to base 10 of the odds ratio.  $\theta$  and its variance  $s^2$  can be obtained by

$$\hat{\theta} = \log\left(\frac{e_t * (n_c - e_c)}{e_c * (n_t - e_t)}\right)$$

$$\hat{s}^2 = 1/e_t + 1/(n_t - e_t) + 1/e_c + 1/(n_c - e_c)$$

Plugging in the observed counts will give the corresponding estimates. The logarithm of the risk ratio  $\theta$  and its variance  $s^2$  is similarly defined as

$$\theta = \log\left(\frac{e_t/n_t}{e_c/n_c}\right) \tag{4.3}$$

$$s^2 = 1/e_t + 1/n_t + 1/e_c + 1/n_c \tag{4.4}$$

Using likelihood theory, one could show that the estimators are maximum likelihood estimators and that one can use the asymptotic normal distribution of the maximum likelihood estimator to calculate a  $p$ -value, e.g. ([Held and Sabanés Bové, 2014](#), 98).

Thus, with  $\Phi$  as the cumulative standard normal distribution, we get

$$p = 2 * (1 - \Phi(|\hat{\theta}/\hat{s}|))$$

, a  $p$ -value for the corresponding estimates, which summarizes the evidence against  $\hat{\theta}$  being zero (i.e. the true risk/odds ratio being 1).

Binary and continuous effect measures can be converted into each other, as described in section 4.6.

### 4.2.3 Survival Outcomes

Time-to-event data with censoring has to be analyzed by special means. One frequently used method to take into account right-censoring is the Cox proportional hazards regression model ([Cox, 1972](#)). Because the method itself is not applied in this thesis, but only the resulting estimates of the parameters are used, the reader is referred to the extensive literature covering

this topic (e.g. [Cox and Oakes \(1984\)](#)).

The so-called hazard ratio estimated by cox p.h. regression is the ratio of the instantaneous risk of experiencing the event between two groups. Because it is a maximum likelihood estimator, one can again use its Wald test statistic to test for equal hazards. Let  $\hat{\theta}$  be an estimate of the log hazard ratio and  $\hat{s}$  an estimate of the standard error of it. As before

$$p = 2 * (1 - \phi(|\hat{\theta}/\hat{s}|))$$

will give a  $p$ -value for the evidence against the null hypothesis.

### 4.3 Fixed and Random Effects Meta-Analysis

The fixed effects meta-analysis estimator of the pooled treatment effect is a mean of the single treatment effect estimators, weighted by their standard errors ([Rosenthal and Rubin, 1982](#)). Let  $w_i = 1/s_i^2$  be the weights, and  $\theta_M$  be the pooled estimator and  $s_M^2$  its variance. Then

$$\theta_M = \frac{\sum_{i=1}^n w_i \theta_i}{\sum_{i=1}^n w_i} \quad s_M^2 = \frac{1}{\sum_{i=1}^n w_i} \quad (4.5)$$

This estimator minimizes the variance between the effects. An estimate  $\hat{\theta}_M$  can be obtained by plugging in the observed treatment effects and variances  $\hat{\theta}_i, \hat{s}_i^2$ . The underlying idea is that we assume  $\theta_i \sim N(\theta_M, s_i^2)$ ,  $\theta_M$  being the true effect, all  $\theta_i$  being distributed around an equal mean.

The random effects model ([Whitehead and Whitehead, 1991](#)) assumes instead that

$$\theta_i \sim N(\mu_i, s_i^2) \quad \mu_i \sim N(\theta_M, \tau^2) \quad (4.6)$$

Marginally, we have  $\theta_i$  being distributed around a common mean  $\theta_M$  with additional variance  $\tau^2$ :

$$\theta_i | \mu_i \sim N(\theta_M, s_i^2 + \tau^2)$$

$\tau^2$  is often referred to as a population variance or between-study variance, whereas  $s_i^2$  can be interpreted as sampling error. The pooled treatment effect estimate  $\theta_M$  of the random effects model and its variance is obtained by replacing the weights  $w_i$  in equation 4.5 with  $w_i = 1/(s_i^2 + \tau^2)$ .

The model is superior to the fixed effects model whenever the standard errors of the treatment effects alone are unlikely to fully account for the entire variability observed between studies. Note that as  $\tau^2$  increases, each  $\theta_i$  will eventually get equal weights, irrespective of its sampling error  $s_i^2$ .

The estimation of  $\tau^2$  has been subject to some debate in the statistical literature. Oftentimes, the method of moment estimator of [DerSimonian and Laird \(1986\)](#) is used. We use the measure of heterogeneity,  $Q$ , and divide by  $C$  after having subtracted the degrees of freedom  $n - 1$ :

$$Q = \sum_{i=1}^n w_i (y_i - \theta_M)^2 \quad C = \sum_{i=1}^n w_i - \frac{\sum_{i=1}^n w_i^2}{\sum_{i=1}^n w_i} \quad (4.7)$$

$$\tau^2 = \max(0, \frac{Q - (n - 1)}{C}) \quad (4.8)$$

Again,  $w_i, \theta_i \dots$  have to be replaced by their estimates in order to get an estimate  $\hat{\tau}^2$ . The Paule-Mandel estimator ([Paule and Mandel, 1982](#)) is considered to have most often better

properties than the method of moments estimator (e.g. [Veroniki et al. \(2016\)](#)). Since we defined  $w_i = 1/(s_i^2 + \tau^2)$ , it also holds that

$$w_i \text{Var}(\theta_i) = 1 \qquad \text{Var}(\sqrt{w_i} \theta_i) = 1$$

For any  $w_i$ , the variance can be estimated and equated to its expected value:

$$s^2(w_i \theta_i) = \frac{\sum_{i=1}^n w_i (\theta_i - \theta_M)^2}{n-1} \qquad \frac{\sum_{i=1}^n w_i (\theta_i - \theta_M)^2}{n-1} = 1 \quad (4.9)$$

$\theta_M$  can be estimated using equation 4.5, the only problem is to estimate  $\tau^2$ . It can be obtained through an iterative process, using a newly defined function

$$F(\tau^2) = \sum_{i=1}^n w_i (\theta_i - \theta_M)^2 - (n-1)$$

In view of equation 4.9,  $\tau^2$  must be such that  $F(\tau^2) = 0$ . Then, we start with an arbitrary  $\tau^2$  and repeatedly add a term  $\tau_0^2$  to update  $\tau^2$  until  $F(\tau^2 + \tau_0^2)$  is close to zero (using  $\tau^2 + \tau_0^2$  for  $\hat{w}_i, \hat{\theta}_M$ ). Using a truncated Taylor series expansion, one can obtain the partial derivative after  $\tau^2$ , which is a reasonable choice for  $\tau_0^2$ .

The estimation of  $\tau^2$  is accompanied by uncertainty. A common procedure is to test if there is significant heterogeneity between the studies ([Borenstein et al., 2011](#), 109). Compute  $Q$ , as given in 4.7, based on one of the estimators of  $\tau^2$ . It is assumed that  $Q$  follows a central Chi-squared distribution with  $n-1$  degrees of freedom under the null hypothesis of equally distributed effect sizes. Thus, the expected value of  $Q$  is  $n-1$ , and the excess dispersion is  $Q - n + 1$ . The  $p$ -value against the null hypothesis of equally distributed effect sizes is  $1 - F(Q)$ , using  $F$  as the cumulative distribution function of the Chi-squared distribution with d.f. =  $n-1$ . An advantage of the  $\tau^2$  is that it is directly linked to the variability in the data. Additionally, one can use the  $I^2$  statistic to see what portion the between study variance has of the overall variance. It is computed as

$$I^2 = (Q - n + 1)/Q$$

Importantly, all proposed methods above assume normally distributed effect sizes and proper estimates  $\hat{s}$  of the true standard error. These assumptions are not met for very small sample sizes and very few event counts. Alternatively, the mantel-haenszel method for risk and odds ratios (see e.g. [Fleiss et al. \(2013\)](#)) could be used in the latter case.

## 4.4 Small Study Effects Tests

The tests that will be presented on the following pages are a common way to detect publication bias. Importantly, they are however not interpretable directly as evidence for publication bias, but this is left for the discussion chapter. The tests are also often referred to as funnel plot asymmetry tests, because of the popularity of a recent test that has been used frequently to test and adjust for publication bias, which goes under the name of trim-and-fill [Duval and Tweedie \(2000\)](#). However, it is known for some time that the method has disadvantageous properties, therefore, it will not be discussed here, as well as the funnel plot (the radial plot will be used as an alternative).

A test for small study effects will test in some ways if the size of the estimated treatment effect of a study depends on some measure of its size. An association between study size and treatment effect size can be interpreted as an artifact of publication bias.



### 4.4.1 Continuous Outcome Tests

For a continuous outcomes that are normally distributed, the sample mean and variance are independent of each other (Schwarzer *et al.*, 2015, 120). Thus, the estimated standard errors of treatment effects can be used as a proxy for study size, as they should in principle not be tied to the effect size.

#### Begg and Mazumdar: Rank Correlation Test

Begg (1988) proposed a rank based test to test the null hypothesis of no correlation between effect size and variance. A standardized effect size  $\theta_i^*$  can be computed as in 4.10.  $s_i^{2*}$  is the variance of  $\theta_i - \theta_M$  as defined in 4.11,  $\theta_M$  being the fixed effects pooled treatment effect (4.5).

$$\theta_i^* = (\theta_i - \theta_M) / s_i^{2*} \quad (4.10)$$

$$s_i^{2*} = s_i^2 - 1 / \sum_{i=1}^n \frac{1}{s_i^2} \quad (4.11)$$

A rank correlation test based on Kendall's tau is then used. First, the pairs are ordered after their ranks based on  $s^{2*}$ . Then, for each  $s^{2*}$  rank, the corresponding ranks based on  $\theta^{2*}$  that are larger are counted and summed up to  $u$ . The number of ranks based on  $\theta^{2*}$  that are in contrary, smaller, are counted and summed up to  $l$ . Then the normalized test statistic  $Z$  is given as

$$Z = (u - l) / \sqrt{n(n-1)(2n+5)/18}$$

Thus, large number of concordance between pairs will reflect in large  $\hat{u}$  and small  $\hat{l}$  and thus lead to a large  $\hat{Z}$ . The  $p$ -value is obtained using the standard normal distribution  $\Phi$ :

$$p = 2 * (1 - \Phi(|Z|))$$

The changes that have to be made into the case of ties are small and can be found in (Begg, 1988, 410).

#### Egger's Test: Weighted Linear Regression Test

First, the concept of simple linear regression is introduced. In short, the model assumes a dependent variable  $y$  to be a linear function of another explanatory variable  $x$ :

$$y = \beta_0 + \beta_1 x + \epsilon, \quad \epsilon \sim N(0, \sigma^2) \quad (4.12)$$

$\epsilon$  is the residual noise term that becomes necessary when  $n$  pairs  $(x_i, y_i)$  are given and there is no exact solution. Then it is common to look for the solution that minimizes the squared residuals, the least-squares solution. Formally,

$$\underset{\beta_0, \beta_1}{\operatorname{argmin}} \left( \sum_{i=1}^n y_i - \beta_0 - \beta_1 x_i \right) \quad (4.13)$$

Let  $\mathbf{X}$  be a matrix with the explanatory variables  $x$  and  $\mathbf{y}$  a corresponding vector for all  $y$ :

$$\mathbf{X} = \begin{bmatrix} 1 & x_{12} \\ 1 & x_{22} \\ 1 & x_{32} \\ \vdots & \vdots \\ 1 & x_{n2} \end{bmatrix} \quad \mathbf{y} = \begin{bmatrix} y_1 \\ y_2 \\ y_3 \\ \vdots \\ y_n \end{bmatrix}$$

Let  $\beta = (\beta_0, \beta_1)^\top$ . It can be shown that

$$\hat{\beta} = (\mathbf{X}^\top \mathbf{X})^{-1} \mathbf{X}^\top \mathbf{y} \quad (4.14)$$

Is an estimator of  $\beta$  that minimizes the squared residuals. Let  $\hat{\mathbf{y}} = \mathbf{X}\hat{\beta}$  and  $\hat{\mathbf{r}} = \hat{\mathbf{y}} - \mathbf{y}$ . The variance estimates  $\hat{\sigma}^2$  and  $\hat{\mathbf{s}}_\beta^2$  are

$$\hat{\sigma}^2 = \frac{1}{n-2} \mathbf{r}^\top \hat{\mathbf{r}} \quad \hat{\mathbf{s}}_\beta^2 = \hat{\sigma}^2 (\mathbf{X}^\top \mathbf{X})^{-1} \quad (4.15)$$

The estimate  $\hat{\beta}_0$  is the intercept and  $\hat{\beta}_1$  the slope of the regression line. Furthermore, in the simple linear regression setting,  $\hat{\beta}_0$  can also be obtained by:

$$\hat{\beta}_0 = \bar{y} - \hat{\beta}_1 \bar{x}$$

$\bar{x}, \bar{y}$  denoting the sample means of the corresponding values  $x_1, \dots, x_n$  and  $y_1, \dots, y_n$ . Thus,  $\hat{\beta}_0$  is also called global mean. To test whether there is evidence for the intercept  $\beta_0$  to be unequal to some value  $\beta_{H0}$ , a  $t$ -test can be used.

$$p = 2(1 - F(|(\beta_0 - \beta_{H0})/s_{\beta_0}|))$$

where  $F$  is the cumulative  $t$  distribution with  $n - 2$  degrees of freedom.  $p$  will give the evidence against the null hypothesis  $\beta_0 = \beta_{H0}$ .

The concept is extendable to weighted linear regression. Weighted linear regression may be used if the residuals  $\mathbf{r}$  have unequal variances, which is equivalent to ascribe different precision to the observed  $y$ . The least squares equation 4.13 is extended to

$$\underset{\beta_0, \beta_1}{\operatorname{argmin}} \left( \sum_{i=1}^n w_i (y_i - \beta_0 - \beta_1 x_i) \right)$$

with positive weights  $w_i$  that penalize large squared residuals for some  $i$  more if  $w_i$  is larger compared to other  $w_i$ .

Let  $\mathbf{W}$  be a  $n \times n$  matrix with  $\mathbf{W}_{ii} = w_i$ , the weights on the diagonal and zeros on the off-diagonals. The estimates in 4.14 and 4.15 can still be used if  $\mathbf{X}$  is exchanged with  $\mathbf{X}^* = \mathbf{W}\mathbf{X}$  and  $\mathbf{y}$  with  $\mathbf{y}^* = \mathbf{W}\mathbf{y}$ .

Now it is shown how linear regression can be used to test dependency of effect sizes on study sizes. The simplest application was introduced by Egger *et al.* (1997). Let  $\theta/s$  be the dependent variable  $y$  and  $1/s$  the explanatory variable  $x$ . If plotted, this corresponds to a radial or Galbraith plot Galbraith (1988). The linear regression equation as introduced before in 4.12 can be written in two ways:

$$\theta/s = \beta_0 + \beta_1/s + \epsilon, \quad \epsilon \sim N(0, \sigma^2) \quad (4.16)$$

4.16 is often provided due to the correspondence to the radial plot. However, it is equivalent to

$$\theta = \beta_0 + \beta_1 s + \epsilon, \quad \epsilon \sim N(0, w^{-1} \sigma^2) \quad (4.17)$$

with weights  $w = 1/s^2$ . Thus testing  $\beta_0$  of 4.16 or  $\beta_1$  is equivalent. The corresponding  $p$ -value is then used as evidence for a small study effect. Plugging in  $\theta_i/s_i, 1/s_i$  as  $y_i, x_i$  into equation 4.14 and 4.15 will give the estimates for  $\hat{\beta}_0, \hat{\beta}_1, \hat{s}_{\beta_0}$  and  $\hat{s}_{\beta_1}$ .

### Thompson and Sharp's Test: Weighted Linear Regression Random Effects Test

A method proposed in [Thompson and Sharp \(1999\)](#) allows for between study variance  $\tau^2$ , as introduced before in section 4.3. It extends the previously seen linear regression approach with  $x = 1/s$  and  $y = \theta/s$  by introducing weights. The effect size  $\theta_i$  is assumed to be distributed as

$$\theta_i \sim N(\beta_0 + \beta_1 s_i, s_i^2 + \tau^2) \quad (4.18)$$

$\tau^2$  is estimated as in equation 4.8 (method of moments). The weights are set as  $w_i = 1/\sqrt{s_i^2 + \tau^2}$ . After adjusting for the weights as described in 4.4.1, we can proceed analogous to Egger's test. The  $p$ -value for  $\beta_0 \neq 0$  reflects the evidence for a small study effect.

#### 4.4.2 Dichotomous Outcomes Tests

The issue with dichotomous outcomes is that effect size and variance of effect size are correlated, which can readily be seen in 4.3 and 4.4. For example, a small number of event counts in one or group will inflate the variance and the effect size. Consequently, the tests above will tend to reject the null-hypothesis too often, i.e. report false positives. A number of solutions to this problem are provided in the literature.

### Peters Test: Weighted Linear Regression Test

Instead of taking the standard error  $s$  as explanatory variable  $x$  as in Egger's Test, the inverse of the total sample size is used. Additionally, the variances  $s_i^2$  are used as weights. Thus, the subsequent test procedure is identical to Egger's test. Peters test is a small modification of Macaskill's test where the explanatory variable is the sample size instead of its inverse.

### Harbord's Test: Score based Test

A rank based alternative to Peters test for binary outcomes is Harbord's test ([Harbord et al., 2006](#)). It uses a different treatment effect and variance estimate: the score  $\varphi$  of the log-likelihood, evaluated at log odds ratio  $\theta_0 = 0$  and its inverse Fisher information  $s^2$ . Formally,

$$\varphi = e_t - (e_t - e_c)(e_t + (n_t - e_t))/(n_t + n_c) \quad (4.19)$$

$$s^2 = \frac{(e_t + e_c)(e_t + (n_t - e_t))(e_c + (n_c - e_c))((n_t - e_t) + (n_c - e_c))}{(n_t + n_c)^2(n_t + n_c - 1)} \quad (4.20)$$

It can be shown that they are both good approximations of the log odds ratio and its variance if the real  $\theta$  is not too far from zero. The standardized estimator  $r_i/v_i$  is also known as Pet0 odds ratio. The obtained scores and variances can be used in Egger's test as treatment effects and variances.

### Schwarzer's Test: Rank Correlation Test

[Schwarzer et al. \(2007\)](#) developed a test for the correlation between  $E_t - \mathbb{E}(E_t)$  and the variance of  $E_t$ ,  $E_t$  being a random variable from the non-central hypergeometric distribution, assuming a fixed log odds ratio.

$\mathbb{E}(E_t)$  and variance of  $E_t$  are then estimated based on  $e_t$ . The standardized cell count deviation

$$(e_t - \mathbb{E}(E_t))/\sqrt{(s_i^2)} \quad (4.21)$$

and the inverse of  $s_i^2$  is then used as before in Begg and Mazumdar's test.

### Rücker's Test: Using the Variance Stabilizing Transformation for Binomial Random Variables

The correlation between variance and effect size of dichotomous outcome measures can be abolished by the variance stabilizing transformation for binomial random variables. We use that the arcsine function is the variance stabilizing transformation for a proportion. Let

$$\theta_i = \arcsin e_t/n_t - \arcsin e_c/n_c s_i^2 = 1/4n_t + +/4n_c$$

Then one can optionally apply Begg and Mazumdar's rank correlation test or Thompson and Sharp's test using the newly obtained estimates.

#### 4.4.3 Excess Significance Test

Ioannidis and Trikalinos (2007b) developed an exploratory test to detect if the proportion of significant findings is larger than expected. Note that significance is here defined as one-sided significance, with the direction of the test being the same for each study.

We assume that the effects are equally distributed around a true mean effect  $\theta_M$ , which can be estimated as for example by fixed effects Meta-Analysis 4.5. Let  $O$  be the number of significant study results out of  $n$  studies and  $\alpha$  the significance threshold. Corresponding to the study effect  $\theta_i$ , we can specify the power  $1 - \beta_i$ , the probability to accepting a true result. Let  $z_{\alpha,i}$  be the  $1 - \alpha$  quantile of a normal distribution with standard error  $\hat{s}_i$ . The power of study  $i$  can be estimated as:

$$1 - \hat{\beta}_i = F(z_\alpha) \quad (4.22)$$

with  $F$  being the cumulative distribution of a normal with mean  $\hat{\theta}_M$  and standard deviation  $\hat{s}_i$ .

If we assume no bias in  $\theta_i, \theta_M$ , the expected number of significant study results is then just

$$E = \sum_{i=1}^n (1 - \beta_i)$$

$E$  can then be compared to  $O$  by constructing a test statistic  $\chi$ :

$$\chi = \left( \frac{(O - E)^2}{E} + \frac{(O - E)^2}{n - E} \right)$$

and consecutively, calculating a  $p$ -value for the evidence against the null-hypothesis of  $O = E$  with a  $\chi^2$  distribution with one degree of freedom. Alternatively, one can also use a binomial proportion test, which tests if the probability of significance is the same as expected. A simple Wald test statistic  $Z$  is given by:

$$Z = \frac{O/n - E/n}{\sqrt{(O/n(1 - O/n))/n}} \quad (4.23)$$

The one sided  $p$ -value for the alternative hypothesis  $O/n > E/n$  is

$$p = 1 - \Phi(Z)$$

with  $\Phi$  being the cumulative distribution function of a standard normal. Ioannidis and Trikalinos (2007b) propose it to be more suitable if  $n$  is small.

## 4.5 Small Study Effect and Publication Bias Adjustment

There are different approaches to correct for small study effects and publication bias. They can mainly be distinguished by their underlying methods: regression based approaches aim to regress the effect to a study with infinite precision (i.e. very small standard error) or to a summary effect, corrected for publication bias. Selection models aim to simulate different, hypothetical selection processes and attain a approximate treatment effect by sensitivity analysis:

### 4.5.1 Adjustment by Regression

Rücker *et al.* (2011) use a random effects model to obtain an unbiased estimate. Similarly to regression based tests for small study effects, we have

$$\theta_i = \beta_0 + \beta_1 \sqrt{s_i^2 + \tau^2} + \epsilon_i \sqrt{v_i + \tau^2}, \epsilon_i \stackrel{\text{iid}}{\sim} N(0, 1) \quad (4.24)$$

The only difference between Thompson and Sharp's variant is  $x = \sqrt{s^2 + \tau^2}$  instead of  $x = \sqrt{s^2}$ .  $\beta_1$  represents the bias introduced by small study effects, as illustrated in the following equations:

$$\begin{aligned} \mathbb{E}((\theta_i - \beta_0)/\sqrt{s_i^2}) &\rightarrow \beta_1 \text{ if } s_i \rightarrow \infty \\ \mathbb{E}(\theta_i) &\rightarrow \beta_0 + \beta_1 \tau \text{ if } s_i \rightarrow 0 \end{aligned}$$

After estimating  $\tau^2$ , one can estimate  $\beta_0$  and  $\beta_1$  as seen before in the simple linear regression framework. Now we have basically two possible estimates at hand:

- $\beta_0$  the treatment effect without any influence of study precision with standard error  $s_{\beta_0}$
- $\beta_0 + \beta_1 \tau$  the treatment effect of a hypothetical study with infinite precision, corresponding standard error  $s_{\beta_0} + s_{\beta_1}$

Simulations in Rücker *et al.* (2011) suggested that the latter estimate is slightly superior with respect to coverage (and mean squared error).

### 4.5.2 Copas Selection Model

A method proposed in Copas and Shi (2001, 2000); Copas and Malley (2008) assumes that the given sample of treatment effects and standard errors is a selected part of a larger random sample. Selection of studies depends on their effect size and variance. Smaller variance is always accompanied by larger selection probability.

Let  $\theta_i$  be the effect size estimate of study  $i$ . Then

$$\theta_i \sim N(\mu_i, \sigma_i^2) \mu_i \sim N(\theta, \tau^2) \quad (4.25)$$

which is similar to the random-effects meta-analysis setting.  $\theta$  is the population mean effect,  $\sigma_i^2$  the within study variance and  $\tau^2$  the between study variance. Equations in 4.25 are termed the *population model*.

The *selection model* is defined as follows. Suppose a selection of studies with reported ( $\neq$  estimated) standard errors  $s$  (likely different from  $\sigma$ ). Only a proportion of the selection will be published, with  $a$  defining the overall proportion of published studies and  $b$  (assumed to be positive) defining how fast this proportion increases with  $s$  becoming smaller. Formally,

$$P(\text{select}|s) = \Phi(a + b/s)$$

The equation can be rewritten as

$$z = a + b/s + \delta$$

with  $\delta \sim N(0, 1)$ .  $z$  is interpreted as the *propensity for selection*. It's sign must be positive in order for the study to be selected. Thus, the larger  $z$ , the more likely the study will be selected. Also,  $a$  is somewhat like to global retention or selection rate for each study, while  $b$  decides about the decline of selection probability with increasing  $s$ .

So far, we have, for a study  $i$

$$\begin{aligned}\theta_i &= \mu_i + \sigma_i \epsilon_i \\ \mu_i &\sim N(\theta, \tau^2) \\ z_i &= a + b/s_i + \delta_i\end{aligned}$$

where  $(\epsilon_i, \delta_i)$  are standard normal residuals. The two models are coupled by introducing a correlation  $\rho = \text{cor}(\theta_i, z_i)$  by defining  $(\epsilon_i, \delta_i)$  as bivariate standard normals. It follows that, if  $\rho_i$  is large and positive and  $z_i > 0$ , then the estimate of a study  $i$  that is selected is likely to have positive  $\epsilon_i$  and  $\delta_i$  and thus, the true mean  $\mu$  is likely to be overestimated.

Let  $u_i = a + b/s_i$ ,  $\lambda(u_i)$  the Mill's ratio  $\phi(u_i)/\Phi(u_i)$  ( $\phi$  is the standard normal density function and  $\Phi$  the cdf) and  $\tilde{\rho}_i = \sigma/\sqrt{(\tau^2 + \sigma_i^2)}\rho_i$ . The probability of a study being selected, given  $s_i$  and  $\theta_i$ , is

$$P(\text{select}|s_i, \theta_i) = \Phi\left(\frac{u_i + \tilde{\rho}_i((\theta_i - \mu)/\sqrt{(\tau^2 + \sigma_i^2)})}{\sqrt{1 - \tilde{\rho}_i^2}}\right)$$

Which again shows that larger  $s_i$  and  $\theta_i$  lead to a larger selection probability. It can also be shown that the expected value

$$\mathbb{E}(\theta_i|s_i, \text{select}) = \mu + \rho_i \sigma_i \lambda(u_i) \quad (4.26)$$

which shows that the expected value for a study is larger for larger  $\sigma$ .

A likelihood for  $\theta_i$ , conditional on  $z > 0$  can be formulated to estimate the parameters of the model. Regarding  $a$  and  $b$ , there is no way that they can be estimated because the number of missing studies and their effect sizes is not known. Instead, fixed values for  $a$  and  $b$  have to be chosen. The nuisance parameter  $\sigma_i$  can be replaced by an estimate if the sample size in the studies is large enough. Since

$$\text{Var}(\theta_i|s_i, z_i > 0) = \sigma_i^2(1 - c_i^2 \rho_i^2)$$

with  $c^2 = \lambda(u_i)(u_i + \lambda(u_i))$ , we can replace  $\sigma_i^2$  by  $\hat{\sigma}_i^2 = \frac{1}{1 - c_i^2 \rho_i^2}$ . Although one has to evaluate the likelihood for fixed pairs  $(a, b)$ , one can compare the fit of the model to evaluate which one is more suitable: With equation 4.26, one can obtain fitted values of  $\theta_i$  based on  $s_i$ . Also, for two different pairs  $(a, b)$ ,  $(a^*, b^*)$ ,

$$\mathbb{E}(\theta_i | z_i > 0, a^*, b^*) - \mathbb{E}(\theta_i | z_i > 0, a, b) \approx c^* + \rho(\lambda(a^*) - \lambda(a))s_i$$

and that local departures of  $\theta_i$  can be approximated by adding a linear term in  $s_i$  to the expectation of  $\theta_i$ . Thus, to test a pair  $(a, b)$ , it is sufficient to test  $\beta \neq 0$  in

$$\theta_i = \theta + \beta s_i + \sigma_i \epsilon_i$$

with restriction that  $\rho \geq 0$ . To test some pair  $(a, b)$  against the scenario with no selection, we set  $a^* = \infty$  (or  $\rho = 0$ ). A likelihood ratio test will give a test statistic to test against  $H_0 =$  no selection:

$$\chi^2 = 2 * (\max_{\theta, \tau, \beta} \tilde{L}(\theta, \tau, \beta) - \max_{\theta, \tau} \tilde{L}(\theta, \tau, 0)) \quad (4.27)$$

with

$$\tilde{L}(\theta, \tau, \beta) = -\frac{1}{2} \sum_{i=1}^n [\log(\tau^2 + \sigma_i^2) + \frac{(\theta_i - \theta - \beta s_i)^2}{(\tau^2 + \sigma_i^2)}]$$

$\chi^2$  can be used with a  $\chi^2$  distribution with one degree of freedom to obtain a  $p$ -value. Note that the test is almost equivalent to Egger's small study effect test with  $\tau^2 = 0$ . Thus, although the copas selection model models publication bias, it is dependent on the small study effects to find the most suitable pair  $(a, b)$ .

If one applies the model to a single meta-analysis, a sensitivity analysis is suggested. One can observe how  $\theta$  and its confidence intervals change dependent on the underlying selection process. Selection models are in general not recommended for inference (e.g. [McShane et al. \(2016\)](#)). [Rücker et al. \(2011\)](#) have shown how the method can be implemented in a simulation for inference purposes.

A range of values of  $(a, b)$  are applied, and the test for residual small study effect as described in equation 4.27 is applied. If all obtained  $p$ -values from the test are above a threshold 0.1, this is interpreted as no evidence, and no need for modelling, and the standard, classical random effects meta-analysis is retained. If none of the  $p$ -values is above the threshold, a wider range of values for  $(a, b)$  is used. When some  $p$ -values are above, and some below the threshold, the pair  $(a, b)$  with the smallest number of missing studies is retained (that is, the least intense underlying selection model is chosen).

Currently, there is no test to detect miss-specifications in the model itself, the authors themselves have argued that a non-parametric test of the residuals would lack power.

## 4.6 Transformation between effect sizes

Assuming that binary outcomes result from a dichotomization of originally continuous random variables, in this case, the logistic distribution, a transformation from typical binary effect measures to Cohen's  $d$  can be achieved ([Borenstein et al., 2011](#), 47).

Let  $\theta$  be a log odds ratio and  $s$  its standard error. Cohen's  $d$  and its variance  $s_d^2$  is obtained by

$$d = \theta \frac{\sqrt{3}}{\pi} \quad s_d^2 = s^2 \frac{\sqrt{3}}{\pi}$$

$\frac{\pi}{\sqrt{3}} = 1.81$  is the standard deviation of the logistic distribution  $L(\mu, \eta)$  with scale parameter  $\eta = 1$ , so we just divide the log odds ratio and its variance through the standard deviation.

The approximation works only well if  $e_t$  and  $e_c$  are not very small, especially in the case of  $s_d^2$ . Plugging in the observed log odds ratio  $\hat{\theta}$  and  $\hat{s}^2$  will give an estimate of Cohen's  $d$ . Pearson's correlation can be attained by the formulas (Hedges and Olkin (1985), (Borenstein *et al.*, 2011, 48))

$$r = \frac{d}{\sqrt{d^2 + a}} \qquad a = (n_c + n_t)^2 / n_c n_t$$

where  $a$  is a correction factor if  $n_t \neq n_c$ . The variance of  $r$ ,  $s_r^2$  is computed by

$$s_r^2 = \frac{a^2 s_d^2}{(d^2 + a)^3}$$

Finally, we can get to a fisher's z-scaled correlation  $z$  and it's variance  $s_z^2$  by using

$$z = 0.5 \ln\left(\frac{1+r}{1-r}\right) \qquad s_z^2 = \frac{1}{n-3}$$



## Appendix A

# Appendix

Maybe some R code here, probably a `sessionInfo()`



# Bibliography

- Begg, C. B. (1988). Statistical methods in medical research p. armitage and g. berry, blackwell scientific publications, oxford, u.k., 1987. no. of pages: 559. price £22.50. *Statistics in Medicine*, **7**, 817–818. [25](#)
- Borenstein, M., Hedges, L. V., Higgins, J. P. T., Rothstein, H. R., and Higgins, D. J. P. T. (2011). *Introduction to Meta-Analysis*. John Wiley & Sons, Incorporated, Hoboken, UNKNOWN. [22](#), [24](#), [31](#), [32](#)
- Copas, J. and Shi, J. Q. (2000). Meta-analysis, funnel plots and sensitivity analysis . *Biostatistics*, **1**, 247–262. [29](#)
- Copas, J. B. and Malley, P. F. (2008). A robust p-value for treatment effect in meta-analysis with publication bias. *Statistics in Medicine*, **27**, 4267–4278. [29](#)
- Copas, J. B. and Shi, J. Q. (2001). A sensitivity analysis for publication bias in systematic reviews. *Statistical Methods in Medical Research*, **10**, 251–265. [29](#)
- Cox, D. and Oakes, D. (1984). *Analysis of Survival Data*. Chapman & Hall. [23](#)
- Cox, D. R. (1972). Regression models and life-tables. *Journal of the Royal Statistical Society: Series B (Methodological)*, **34**, 187–202. [22](#)
- DerSimonian, R. and Laird, N. (1986). Meta-analysis in clinical trials. *Controlled Clinical Trials*, **7**, 177 – 188. [23](#)
- Duval, S. and Tweedie, R. (2000). Trim and fill: A simple funnel-plot based method of testing and adjusting for publication bias in meta-analysis. *Biometrics*, **56**, 455–463. [24](#)
- Egger, M., Smith, G. D., Schneider, M., and Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. *BMJ*, **315**, 629–634. [26](#)
- Fleiss, J. L., Levin, B., and Paik, M. C. (2013). *Statistical methods for rates and proportions*. John Wiley & Sons. [24](#)
- Galbraith, R. F. (1988). A note on graphical presentation of estimated odds ratios from several clinical trials. *Statistics in Medicine*, **7**, 889–894. [26](#)
- Harbord, R. M., Egger, M., and Sterne, J. A. C. (2006). A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. *Statistics in Medicine*, **25**, 3443–3457. [27](#)
- Hedges, L. V. and Olkin, I. (1985). Chapter 11 - combining estimates of correlation coefficients. In Hedges, L. V. and Olkin, I., editors, *Statistical Methods for Meta-Analysis*, 223 – 246. Academic Press, San Diego. [32](#)
- Held, L. and Sabanés Bové, D. (2014). Applied statistical inference. *Springer, Berlin Heidelberg*, doi, **10**, 978–3. [22](#)

- Higgins JPT, G. S. (2011). *Cochrane Handbook for Systematic Reviews of Interventions*. The Cochrane Collaboration. 3
- Ioannidis, J. P. and Trikalinos, T. A. (2007a). The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. *CMAJ*, **176**, 1091–1096. 10
- Ioannidis, J. P. and Trikalinos, T. A. (2007b). An exploratory test for an excess of significant findings. *Clinical Trials*, **4**, 245–253. 13, 28
- Kasuya, E. (2001). Mann-whitney u test when variances are unequal. *Animal Behaviour*, **6**, 1247–1249. 22
- McShane, B. B., Böckenholt, U., and Hansen, K. T. (2016). Adjusting for publication bias in meta-analysis: An evaluation of selection methods and some cautionary notes. *Perspectives on Psychological Science*, **11**, 730–749. 31
- Paule, R. C. and Mandel, J. (1982). Consensus values and weighting factors. *Journal of Research of the National Bureau of Standards*, **87**, 377–385. 23
- Rosenthal, R. and Rubin, D. B. (1982). Comparing effect sizes of independent studies. *Psychological Bulletin*, **92**, 500–504. 23
- Rücker, G., Carpenter, J. R., and Schwarzer, G. (2011). Detecting and adjusting for small-study effects in meta-analysis. *Biometrical Journal*, **53**, 351–368. 29, 31
- Schwarzer, G., Antes, G., and Schumacher, M. (2007). A test for publication bias in meta-analysis with sparse binary data. *Statistics in Medicine*, **26**, 721–733. 27
- Schwarzer, G., Carpenter, J. R., and Rücker, G. (2015). *Meta-analysis with R*, volume 4724. Springer. 25
- Thompson, S. G. and Sharp, S. J. (1999). Explaining heterogeneity in meta-analysis: a comparison of methods. *Statistics in Medicine*, **18**, 2693–2708. 27
- Veroniki, A. A., Jackson, D., Viechtbauer, W., Bender, R., Bowden, J., Knapp, G., Kuss, O., Higgins, J. P., Langan, D., and Salanti, G. (2016). Methods to estimate the between-study variance and its uncertainty in meta-analysis. *Research Synthesis Methods*, **7**, 55–79. 24
- Whitehead, A. and Whitehead, J. (1991). A general parametric approach to the meta-analysis of randomized clinical trials. *Statistics in Medicine*, **10**, 1665–1677. 23